Expanding role of biologic agents in rheumatoid arthritis

Journal of Rheumatology

Volumn 29, Issue SUPPL. 66, 2002, Pages 27-37

  Kalden, Joachim R ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Biologics; Drug therapy; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT;

CONFERENCE PAPER; DISABILITY; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; MORTALITY; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIDE EFFECT; STATISTICAL ANALYSIS; CLINICAL TRIAL; DISEASE COURSE; DRUG COMBINATION; IMMUNOLOGY; METHODOLOGY; PATHOLOGY; REVIEW; RHEUMATOLOGY;

ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CLINICAL TRIALS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; RHEUMATOLOGY;

EID: 0036843121     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (73)

1. Lipsky PE, Kavanaugh A. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies. Rheumatology 1999;38 Suppl 2:41-4.
2. Sangha O. Epidemiology of rheumatic diseases. Rheumatology 2000;39 Suppl 2:3-12.
3. March L, Lapsley H. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis? Best Pract Res Clin Rheumatol 2001;15:171-85.
4. Tugwell P. Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology 2000;39 Suppl 1:43-7.
5. Maini R, St. Clair EW, Breedveld F, et al. for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999;354:1932-9.
6. Suarez-Almazor ME. In quest of the Holy Grail: Efficacy versus effectiveness in rheumatoid arthritis. J Rheumatol 2002;29:209-11.
7. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
8. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
9. Klippel JH. Biologic therapy for rheumatoid arthritis. N Engl J Med 2000:343:1640-1.
10. Kalden JR. How do the biologics fit into the current DMARD armamentarium? J Rheumatol 2001;28 Suppl 62:27-35.
11. Breedveld FC. Future trends in the treatment of rheumatoid arthritis: Cytokine targets. Rheumatology 1999;38 Suppl 2:11-3.
12. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999;26 Suppl 57:16-21.
13. Emery P, Buch M. Treating rheumatoid arthritis with tumour necrosis factor α blockade. BMJ 2002;324:312-3.
14. Kempeni J. Update on D2E7: A fully human anti-tumour necrosis factor α monoclonal antibody. Ann Rheum Dis 2000;59 Suppl 1:i44-i45.
15. Maini R, Brennan F, Williams R, et al. TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 1993;11 Suppl 8:S173-S175.
16. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
17. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 1996;319:516-8.
18. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
19. Thornton SC, Por SB, Penny R, et al. Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumor necrosis factor-alpha. Clin Exp Immunol 1991;86:79-86.
20. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322:547-9.
21. Von Asmuth EJU, van der Linden CJ, Leeuwenberg JFM, Buurman WA. Involvement of the CD11b/CD18 integrin, but not of the endothelial cell adhesion molecules ELAM-1 and ICAM-1 in tumor necrosis factor - Induced neutrophil toxicity. J Immunol 1991;147:3869-75.
22. 2, interleukin 1α, and tumor necrosis factor-α increase human osteoclast formation and bone resorption in vitro. Endocrinology 1998;139:3157-64.
23. Paleolog EM, Hunt M, Elliott MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
24. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
25. Moreland L, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
26. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF alpha treatment. Ann Rheum Dis 1999;58 Suppl 1:i61-i64.
27. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
28. Spencer-Green G. Etanercept (Enbrel): Update on therapeutic use. Ann Rheum Dis 2000;59 Suppl 1:i46-i49.
29. van den Berg WB. Lessons for joint destruction from animal models. Curr Opin Rheumatol 1997;7:221-8.
30. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta and IL-1Ra. Arthritis Rheum 1996;39:797-809.
31. Feldman M, Miotla J, Paleolog E, et al. Future prospects for anti-cytokine treatment. Ann Rheum Dis 2000;59 Suppl I:119-22.
32. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002;46:328-46.
33. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
34. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
35. Paulus HE, Egger MJ, Ward JR, Williams JH and The Cooperative Systemic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
36. Lovell DJ, Giannini EH, Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
37. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
38. Moreland LW, Schiff MH, Baumgartner SW, et al. Phase III trial of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc, ENBREL) [abstract]. J Invest Med 1998;46:228A.
39. Keystone E, Weinblatt M, Furst D, et al. The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate [abstract]. Arthritis Rheum 2001;44 Suppl:S213.
40. Furst D, Keystone E, Weinblatt M, et al. TNF blockade by the fully human monoclonal antibody, adalimumab (D2E7), in the ARMADA trial results in decreases in serum matrix metalloproteinase levels along with impressive clinical improvement in refractory RA patients [abstract]. Arthritis Rheum 2001;44 Suppl:S215.
41. Emery P. The New Science of Rheumatoid Arthritis Treatment [Online Symposium]. Medscape [internet]. [cited August 1, 2002]. Available from: http://www.medscape.com/viewprogram/628
42. den Broeder AA, Joosten LAB, Saxne T, et al. Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61:311-8.
43. Keystone E, Choy E, Kalden J, et al. [LB-3] CDP870, a novel, pegylated, humanized TNF-α inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis [late abstract]. American College of Rheumatology 65th Annual Scientific Meeting, November 10-15, 2001 [Internet] [cited August 1, 2002]. Available from: http://www.abstracts-on-line.com/abstracts/ACR/search
44. Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis 1999;58 Suppl 1:196-8.
45. Kineret™ (Anakinra) Package Insert. Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799.
46. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002;46:614-24.
47. Jiang Y, Genant HK, Watt I, et al. A multicentre, double-blind, dose ranging, randomized and placebo controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiological progression and correlation of Genant and Larsen scoring methods. Arthritis Rheum 2000;43:1001-9.
48. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
49. Taylor PC, Steuer A, Charles P, et al. Early RA patients on infliximab therapy show significant changes in sonographic measures of joint vascularity and serum VEGF by 18 weeks [abstract]. Arthritis Rheum 2001;44 Suppl:S152.
50. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
51. Genovese M, Martin R, Fleischmann R, et al. Etanercept (Enbrel®) in early erosive rheumatoid arthritis (ERA trial): Observations at 3 years [abstract]. Arthritis Rheum 2001;44 Suppl:S78.
52. Silman A, Klareskog L, Breedveld F, et al. Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: The EULAR Surveillance Register for Biological Compounds. Ann Rheum Dis 2000;59:419-20.
53. Wallis WJ, Burge DJ, Jolman J, Spencer-Green G, Gardiner M. Infection reports with etanercept (Enbrel®) therapy [abstract]. Arthritis Rheum 2001;44 Suppl:S78.
54. Lipani JA, Strand V, Johnson K, et al, for the OMERACT Drug Safety Working Party. A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis. J Rheumatol 2001;28:1170-3.
55. Hanauer SB. Review article: Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13 Suppl 4:16-22.
56. Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000;14 Suppl C:29C-32C.
57. Kavanaugh A, St. Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841-50.
58. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
59. Furst DE, Keystone EC, Breedveld FC, et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 2001;60 Suppl 3:iii2-iii5.
60. Klareskog L, Moreland LM, Cohen SB, Sanda M, Burge DJ. Global safety and efficacy of up to five years of etanercept (Enbrel®) therapy [abstract]. Arthritis Rheum 2001;44 Suppl:S77.
61. Moreland LW, Cohen SB, Baumgartner SW, et al. Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
62. Cooper NJ. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology 2000;39:28-33.
63. Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. J Rheumatol 1989;16:867-84.
64. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
65. Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 2001;19:715-28.
66. Furst DE, Breedveld FC, Burmester GR, et al. Consensus statement. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis 1999;58 Suppl 1:i12-30.
67. Furst DE, Breedveld FC, Burmester GR, et al. Consensus statement. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Ann Rheum Dis 2000;59 Suppl 1:i1-i2.
68. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
69. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
70. Elliot MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
71. Garrison L, McDonnell ND. Etanercept: Therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58 Suppl I:i65-i69.
72. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 1999;48:1-4.
73. Smolen JS, Breedveld FC, Burmester GR, et al. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000;59:504-5.